Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine, Venetoclax, and Gilteritinib in FLT3-Mutated AML, CMML, or MDS/MPN
NCT04140487Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2019
- Primary completion
- Sep 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of gilteritinib in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2019; status: recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04140487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04140487.